Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Wang, Bao Zhong ^a   Xu, Rui ^a   Quan, Fu Shi ^a   Kang, Sang Moo ^a   Wang, Li ^a   Compans, Richard W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLAGELLIN; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; INFLUENZA A PR8 (H1N1) VIRUS LIKE PARTICLE VACCINE; INFLUENZA VACCINE; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE ANCHORED FLAGELLIN; RECOMBINANT SOLUBLE FLAGELLIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS ANTIBODY;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL CULTURE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H3N2; LD 50; LUNG LAVAGE; MOUSE; MUCOSAL IMMUNITY; NASAL WASH; NONHUMAN; NOSE; SPLEEN CELL; SURVIVAL; TH1 CELL; TH2 CELL; TRACHEA; TRACHEAL WASH; VIRUS LIKE AGENT; VIRUS LOAD; VIRUS NEUTRALIZATION; WEIGHT REDUCTION; ANIMAL; ARMYWORM; BLOOD; CELL LINE; CELL MEMBRANE; CHICK EMBRYO; DRUG EFFECT; GENETICS; HEMAGGLUTINATION TEST; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INTRANASAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; ORTHOMYXOVIRUS INFECTION; SERODIAGNOSIS; T LYMPHOCYTE; VIRION; VIROLOGY;

INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CELL MEMBRANE; CHICK EMBRYO; FLAGELLIN; HEMAGGLUTINATION TESTS; IMMUNITY, MUCOSAL; IMMUNIZATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; SPODOPTERA; T-LYMPHOCYTES; VIRION;

EID: 78649759121     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013972     Document Type: Article

References (45)

1. Eriksson K, Holmgren J (2002) Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 14: 666-672.
2. Vyas SP, Gupta PN (2007) Implication of nanoparticles/microparticles in mucosal vaccine delivery. Expert Rev Vaccines 6: 401-418.
3. Nugent J, Po AL, Scott EM (1998) Design and delivery of non-parenteral vaccines. J Clin Pharm Ther 23: 257-285.
4. Kuno-Sakai H, Kimura M, Ohta K, Shimojima R, Oh Y, et al. (1994) Developments in mucosal influenza virus vaccines. Vaccine 12: 1303-1310.
5. Tumpey TM, Renshaw M, Clements JD, Katz JM (2001) Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic crossprotection against lethal influenza A H5N1 virus infection. J Virol 75: 5141-5150.
6. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR (2002) A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxinbased adjuvants. Vaccine 20: 2431-2438.
7. Freytag LC, Clements JD (2005) Mucosal adjuvants. Vaccine 23: 1804-1813.
8. McCluskie MJ, Weeratna RD, Clements JD, Davis HL (2001) Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants. Vaccine 19: 3759-3768.
9. Gregoriadis G (1990) Immunological adjuvants: a role for liposomes. Immunol Today 11: 89-97.
10. Okada H, Toguchi H (1995) Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 12: 1-99.
11. Singh M, O'Hagan D (1999) Advances in vaccine adjuvants. Nat Biotechnol 17: 1075-1081.
12. Carrat F, Flahault A (2007) Influenza vaccine: the challenge of antigenic drift. Vaccine 25: 6852-6862.
13. Poland GA, Jacobson RM, Targonski PV (2007) Avian and pandemic influenza: an overview. Vaccine 25: 3057-3061.
14. Takahashi T, Kanda T, Yamaguchi N (2007) Influenza vaccines. N Engl J Med 356: 1172-1173; author reply 1173.
15. Palese P, Garcia-Sastre A (2002) Influenza vaccines: present and future. J Clin Invest 110: 9-13.
16. Smith KD, Andersen-Nissen E, Hayashi F, Strobe K, Bergman MA, et al. (2003) Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 4: 1247-1253.
17. Moors MA, Li L, Mizel SB (2001) Activation of interleukin-1 receptor-associated kinase by gram-negative flagellin. Infect Immun 69: 4424-4429.
18. Mizel SB, Honko AN, Moors MA, Smith PS, West AP (2003) Induction of macrophage nitric oxide production by Gram-negative flagellin involves signaling via heteromeric Toll-like receptor 5/Toll-like receptor 4 complexes. J Immunol 170: 6217-6223.
19. Cuadros C, Lopez-Hernandez FJ, Dominguez AL, McClelland M, Lustgarten J (2004) Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 72: 2810-2816.
20. Honko AN, Sriranganathan N, Lees CJ, Mizel SB (2006) Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 74: 1113-1120.
21. Neutra MR, Kozlowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158.
22. Takahashi I, Nochi T, Yuki Y, Kiyono H (2009) New horizon of mucosal immunity and vaccines. Curr Opin Immunol 21: 352-358.
23. Parham P (2000) The immune system. London: Garland Publishing/Elsevier Science Ltd. pp 31-54.
24. Kang SM, Compans RW (2003) Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. J Virol 77: 3615-3623.
25. Kang SM, Yao Q, Guo L, Compans RW (2003) Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B. J Virol 77: 9823-9830.
26. Mestecky J, Moro I, Kerr MA, Woof JM, eds (2005) Mucosal Immunology. 3rd ed. San Diego: Academic Press. pp 153-182.
27. Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol 21: 335-376.
28. McSorley SJ, Ehst BD, Yu Y, Gewirtz AT (2002) Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo. J Immunol 169: 3914-3919.
29. Skountzou I, Martin MD, Wang B, Ye L, Koutsonanos D, et al. (2010) Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 28: 4103-4112.
30. Nempont C, Cayet D, Rumbo M, Bompard C, Villeret V, et al. (2008) Deletion of flagellin's hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity. J Immunol 181: 2036-2043.
31. Wang BZ, Quan FS, Kang SM, Bozja J, Skountzou I, et al. (2008) Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol 82: 11813-11823.
32. Kreijtz JH, Suezer Y, de Mutsert G, van Amerongen G, Schwantes A, et al. (2009) MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. PLoS One 4: e7790.
33. Levi R, Arnon R (1996) Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. Vaccine 14: 85-92.
34. Hay AJ, Gregory V, Douglas AR, Lin YP (2001) The evolution of human influenza viruses. Philos Trans R Soc Lond B Biol Sci 356: 1861-1870.
35. Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, et al. (2008) Crossprotection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination- inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 26: 1525-1529.
36. Baras B, Stittelaar KJ, Simon JH, Thoolen RJ, Mossman SP, et al. (2008) Crossprotection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 3: e1401.
37. Sambhara S, Kurichh A, Miranda R, Tumpey T, Rowe T, et al. (2001) Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 211: 143-153.
38. Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H (2003) Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21: 3212-3218.
39. Quan FS, Compans RW, Nguyen HH, Kang SM (2008) Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol 82: 1350-1359.
40. Schoenborn JR, Wilson CB (2007) Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96: 41-101.
41. Novak M, Moldoveanu Z, Schafer DP, Mestecky J, Compans RW (1993) Murine model for evaluation of protective immunity to influenza virus. Vaccine 11: 55-60.
42. Sha Z, Compans RW (2000) Induction of CD4(+) T-cell-independent immunoglobulin responses by inactivated influenza virus. J Virol 74: 4999-5005.
43. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoint. American J Hygiene 27: 5.
44. Quan FS, Huang C, Compans RW, Kang SM (2007) Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 81: 3514-3524.
45. Compans RW (1974) Hemagglutination-inhibition: rapid assay for neuraminic acid-containing viruses. J Virol 14: 1307-1309.